Martin Schulze

Durable clinical and immunologic response to an off-the-shelf EWSR1–FLI1 peptide vaccine in metastatic Ewing sarcoma

Abstract Ewing sarcoma is a rare, fusion-driven malignancy with poor prognosis in the metastatic setting, for which no established immunotherapeutic treatment is currently available. Fusion breakpoints are rational precision immunotherapy targets, yet clinical evidence of immunog...